- Home
- MTLS vs ZBIO Comparison
MTLS vs ZBIO Comparison
Compare MTLS & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTLS
- ZBIO
- Stock Information
- Founded
- MTLS 1990
- ZBIO 2019
- Country
- MTLS Belgium
- ZBIO United States
- Employees
- MTLS N/A
- ZBIO N/A
- Industry
- MTLS Computer Software: Prepackaged Software
- ZBIO
- Sector
- MTLS Technology
- ZBIO
- Exchange
- MTLS Nasdaq
- ZBIO NYSE
- Market Cap
- MTLS 297.1M
- ZBIO 268.7M
- IPO Year
- MTLS 2014
- ZBIO 2024
- Fundamental
- Price
- MTLS $5.24
- ZBIO $8.25
- Analyst Decision
- MTLS Buy
- ZBIO Strong Buy
- Analyst Count
- MTLS 1
- ZBIO 6
- Target Price
- MTLS $9.50
- ZBIO $31.83
- AVG Volume (30 Days)
- MTLS 521.2K
- ZBIO 136.9K
- Earning Date
- MTLS 04-24-2025
- ZBIO 03-25-2025
- Dividend Yield
- MTLS N/A
- ZBIO N/A
- EPS Growth
- MTLS 106.79
- ZBIO N/A
- EPS
- MTLS 0.24
- ZBIO N/A
- Revenue
- MTLS $276,182,835.00
- ZBIO $5,000,000.00
- Revenue This Year
- MTLS $6.55
- ZBIO N/A
- Revenue Next Year
- MTLS $9.21
- ZBIO N/A
- P/E Ratio
- MTLS $22.23
- ZBIO N/A
- Revenue Growth
- MTLS 4.15
- ZBIO N/A
- 52 Week Low
- MTLS $4.70
- ZBIO $5.83
- 52 Week High
- MTLS $9.69
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- MTLS 34.03
- ZBIO N/A
- Support Level
- MTLS $4.87
- ZBIO N/A
- Resistance Level
- MTLS $5.13
- ZBIO N/A
- Average True Range (ATR)
- MTLS 0.24
- ZBIO 0.00
- MACD
- MTLS 0.01
- ZBIO 0.00
- Stochastic Oscillator
- MTLS 30.17
- ZBIO 0.00
About MTLS Materialise NV
Materialise NV is a provider of 3D printing services. The products and services of the group are organized in three segments: Medical segment, which develops and delivers medical software solutions, medical devices, and other related products and services; Software segment, which develops and delivers additive manufacturing software solutions and related services; and Manufacturing segment, which delivers 3D printed products and related services. Its geographical segments are the United States, the Americas (excluding the USA), Belgium, Germany, Poland, France, Switzerland, the United Kingdom, Italy, the Netherlands, Other Europe, and the Asia Pacific.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.